Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 36Leukemia 26Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Gastrointestinal Stromal Tumors 13Leukemia, Myeloid, Chronic-Phase 12Leukemia, Myeloid 6Brain Neoplasms 6Prostatic Neoplasms 5Philadelphia Chromosome 5Blast Crisis 5Sarcoma 4Recurrence 4Glioblastoma 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Ovarian Neoplasms 3Melanoma 3Lung Neoplasms 3Leukemia, Myeloid, Acute 3Hematologic Diseases 3Bronchiolitis Obliterans Syndrome 3Breast Neoplasms 3Stomach Neoplasms 2Polycythemia Vera 2Neurofibromatoses 2Neoplasms by Histologic Type 2Neoplasms 2Neoplasm Metastasis 2Myeloproliferative Disorders 2Meningioma 2

Interventions

bosutinib 1Imatinib Mesylate 1Cholecalciferol 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Pathologic Processes × Imatinib Mesylate × Clear all
NCT02130557 2021-05-18

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Pfizer

Phase 3 Completed
536 enrolled 24 charts 1 FDA
MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Pathologic Processes, Philadelphia Chromosome, Translocation, Genetic, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡